依折麦布联合阿托伐他汀对冠心病患者血脂水平、心功能及IMT的影响  

Influence of ezetimibe combined atorvastatin on blood lipid levels,heart function and IMT in patients with coronary heart disease

作　　者：姚颖 张敏[2] 王磊[3] 张俊 YAO Ying;ZHANG Min;WANG Lei;ZHANG Jun(Department of Laboratory,Affiliated Hospital of Yangzhou University,Yangzhou,Jiangsu,225100,China)

机构地区：[1]扬州大学附属医院检验科,江苏扬州225100 [2]扬州大学附属医院门诊部,江苏扬州225100 [3]扬州大学附属医院病理科,江苏扬州225100

出　　处：《心血管康复医学杂志》2021年第4期423-427,共5页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:研究依折麦布联合阿托伐他汀对冠心病患者血脂水平、心功能及颈动脉内膜-中层厚度(IMT)的影响。方法:于我院治疗的128例冠心病患者被随机均分为阿托伐他汀组(在常规治疗基础上加用阿托伐他汀)与联合治疗组(在阿托伐他汀组基础上加用依折麦布),两组均治疗60d。观察比较两组治疗前后甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平、左室舒张末期内径(LVEDd)、左室收缩末期内径(LVESd)、LVEF、IMT以及治疗6个月后主要不良心血管事件(MACE)发生率。结果:与阿托伐他汀组比较,联合治疗组治疗后TG[(1.43±0.14)mmol/L比(1.35±0.12)mmol/L]、TC[(5.29±0.51)mmol/L比(5.03±0.54)mmol/L]、LDL-C[(2.93±0.34)mmol/L比(2.71±0.27)mmol/L]水平、LVEDd[(55.77±5.81)mm比(53.45±5.59)mm]、LVESd[(40.52±4.33)mm比(38.91±4.13)mm]、IMT[(0.96±0.10)mm比(0.91±0.08)mm]降低更显著,HDL-C水平[(1.12±0.11)mmol/L比(1.22±0.12)mmol/L]、LVEF[(46.30±4.25)%比(50.63±5.30)%]升高更显著,P<0.05或<0.01。联合治疗组治疗6个月后MACE发生率显著低于阿托伐他汀组(3.13%比14.06%,P=0.028)。结论:依折麦布联合阿托伐他汀能显著改善冠心病患者血脂水平及心功能,降低颈动脉内膜-中层厚度,安全性好,值得推广。Objective:To study influence of ezetimibe combined atorvastatin on blood lipid levels,heart function and carotid artery intima-media thickness(IMT)in patients with coronary heart disease(CHD).Methods:A total of 128 CHD patients treated in our hospital were randomly and equally divided into atorvastatin group(received atorvastatin based on routine treatment)and combined treatment group(received ezetimibe based on atorvastatin group).Both groups were treated for 60d.Levels of triglycerides(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-C)and high density lipoprotein cholesterol(HDL-C),left ventricular end-diastolic diameter(LVEDd),left ventricular end-systolic diameter(LVESd),LVEF,IMT and incidence rate of major adverse cardiovascular events(MACE)6 months after treatment were observed and compared between two groups.Results:Compared with atorvastatin group after treatment,there were significant reductions in levels of TG[(1.43±0.14)mmol/L vs.(1.35±0.12)mmol/L],TC[(5.29±0.51)mmol/L vs.(5.03±0.54)mmol/L],LDL-C[(2.93±0.34)mmol/L vs.(2.71±0.27)mmol/L],LVEDd[(55.77±5.81)mm vs.(53.45±5.59)mm],LVESd[(40.52±4.33)mm vs.(38.91±4.13)mm]and IMT[(0.96±0.10)mm vs.(0.91±0.08)mm],and significant rise in HDL-C level[(1.12±0.11)mmol/L vs.(1.22±0.12)mmol/L]and LVEF[(46.30±4.25)%vs.(50.63±5.30)%]in combined treatment group,P<0.05 or<0.01.Incidence rate of MACE on 6 months after treatment in combined treatment group was significantly lower than that of atorvastatin group(3.13%vs.14.06%,P=0.028).Conclusion:Ezetimibe combined atorvastatin can significantly improve blood lipid levels and heart function,and reduce IMT in patients with coronary heart disease,with good safety.

关 键 词：冠心病 颈动脉内膜中膜厚度 心功能 药物疗法 联合 

分 类 号：R541.4[医药卫生—心血管疾病]